India's SMS Pharma gains after unit gets US drug regulator approval for Ranitidine

SMS Pharmaceuticals

26/11/2025 05:35

** Pharma manufacturer SMS Pharmaceuticals SMSP.NS rises as much as 8.57% to 297 rupees apiece

** SMSP's unit VKT Pharma gets U.S. drug regulator for reformulated Ranitidine tablets, used to reduce acidity

** Approval marks the re-entry of the acidity drug to the U.S. market after a five-year absence

** Ranitidine, a common antacid drug, was banned by the U.S. in 2020 due to products containing higher levels of NDMA, a probable human carcinogen, says U.S. FDA

** SMSP has risen 14.5% in 2025 so far, exchange data shows

 (Reporting by Bharath Rajeswaran in Bengaluru)

 ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))